Literature DB >> 34237777

Hemifacial Spasm: Comparison of Results between Patients Older and Younger than 70 Years Operated on with Microvascular Decompression.

Hua Zhao1, Jin Zhu1, Yin-da Tang1, Lin Shen1, Shi-Ting Li1.   

Abstract

OBJECTIVE: The aim of the present study was to evaluate the efficacy and safety of microvascular decompression (MVD) for primary hemifacial spasm (HFS) in patients aged ≥70 years and to compare the outcome with a control cohort of younger patients(<70 years).
METHODS: In this retrospective study, subjects were divided into two groups: an elderly group (patients who were ≥70 years) and a younger group. We compared demographic and clinical data, surgical outcome, MVD-related complications, and duration of operation and hospitalization after MVD between the two groups.
RESULTS: At a mean follow-up of 32 ± 4.2 months, 188 elderly patients (90.4%) reported an effective outcome without need for any medication versus 379 (91.1%) of the younger cohort. There was no mortality in both cohorts. The prevalence of delayed facial palsy was 4.8% in the elderly group and 4.1% in the younger group. One (0.5%) patient in the elderly group and 3 (0.7%) patients in the younger group suffered cerebrospinal fluid (CSF) leakage. There was no significant difference between the two groups in terms of MVD-related complications, such as delayed facial palsy, hearing impairment, CSF leakage, and hematoma.
CONCLUSIONS: MVD is an effective treatment option in elderly patients with HFS as well as in younger patients. Age itself seems to be no relevant contraindication or, alternatively, risk factor regarding MVD. Thieme. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 34237777     DOI: 10.1055/s-0040-1721018

Source DB:  PubMed          Journal:  J Neurol Surg A Cent Eur Neurosurg        ISSN: 2193-6315            Impact factor:   1.268


  1 in total

1.  Bibliometric analysis of studies on the treatment of hemifacial spasm.

Authors:  Li-Jun Fang; Chen-Yao Wang
Journal:  Front Neurol       Date:  2022-09-01       Impact factor: 4.086

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.